Assenagon Asset Management
PTGX icon

Assenagon Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Assenagon Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65,756
Closed -$4.37M – 1237
2025
Q3 		$4.37M Sell
65,756
-26,119
-28% -$1.48M 0.01% 642
2025
Q2 		$5.08M Buy
91,875
+47,003
+105% +$2.26M 0.01% 569
2025
Q1 		$2.17M Sell
44,872
-7,367
-14% -$309K ﹤0.01% 744
2024
Q4 		$2.02M Buy
+52,239
New +$2.28M ﹤0.01% 954

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Assenagon Asset Management's PTGX Position: Q4 2025 in Review

Assenagon Asset Management sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 65,756 shares — an estimated $4.37M sold.

Assenagon Asset Management first reported a position in PTGX in Q4 2024 and held it in 4 quarters. The position peaked at $5.08M in Q2 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Assenagon Asset Management reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 65,756 Protagonist Therapeutics shares in Q4 2025, an estimated $4.37M.
  • Assenagon Asset Management first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 4 quarters.
  • Assenagon Asset Management's Protagonist Therapeutics position peaked at $5.08M in Q2 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Assenagon Asset Management's 13F filing for Q4 2025, filed 9 Jan 2026.